|Bid||342.00 x 0|
|Ask||342.05 x 0|
|Day's range||339.75 - 343.35|
|52-week range||290.55 - 345.55|
|Beta (5Y monthly)||0.26|
|PE ratio (TTM)||20.70|
|Forward dividend & yield||9.10 (3.06%)|
|Ex-dividend date||18 Mar 2021|
|1y target est||N/A|
European Commission grants approval to AbbVie (ABBV)/Roche's Venclyxto-based combinations for adults with newly diagnosed acute myeloid leukaemia
Leading the call will be Dr. Helen Torley, Halozyme's President and Chief Executive Officer, who will provide an update on our business; and Elaine Sun, our Chief Financial Officer, who will review our financial results for the first quarter. Thank you, Al. I'm pleased to report that our first quarter results provided a strong start to 2021 for Halozyme.
Ionis (IONS) Q1 adjusted loss per share was wider than the year-ago figure. The company maintains its guidance for 2021.